Convalescent Plasma Reduces Mortality and Decreases Hospitalization Stay in Patients with Moderate COVID-19 Pneumonia

Humans infected with SARS-CoV-2 may develop COVID-19, which manifests across a wide spectrum of clinical severity ranging from mild upper respiratory tract illnesses to diffuse viral pneumonia, causing acute respiratory failure. Many therapies have been tested for their efficacy in treating COVID-19...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Maamoun Basheer, Elias Saad, Dorin Shlezinger, Nimer Assy
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
Acceso en línea:https://doaj.org/article/39c341d34bd845b8a70eddb50ac35c47
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:39c341d34bd845b8a70eddb50ac35c47
record_format dspace
spelling oai:doaj.org-article:39c341d34bd845b8a70eddb50ac35c472021-11-25T18:20:43ZConvalescent Plasma Reduces Mortality and Decreases Hospitalization Stay in Patients with Moderate COVID-19 Pneumonia10.3390/metabo111107612218-1989https://doaj.org/article/39c341d34bd845b8a70eddb50ac35c472021-11-01T00:00:00Zhttps://www.mdpi.com/2218-1989/11/11/761https://doaj.org/toc/2218-1989Humans infected with SARS-CoV-2 may develop COVID-19, which manifests across a wide spectrum of clinical severity ranging from mild upper respiratory tract illnesses to diffuse viral pneumonia, causing acute respiratory failure. Many therapies have been tested for their efficacy in treating COVID-19. Controversy surrounds convalescent plasma transfusions as an effective treatment for COVID-19. This study discusses the efficacy of this treatment on COVID-19 patients. Electronic medical record data were collected from patients diagnosed with COVID-19, from November 2020 to August 2021, in the Galilee Medical Center’s COVID-19 departments. Epidemiological, clinical, laboratory and imaging variables were analyzed. Multivariate stepwise regression and discriminant analyses were used to identify and validate the correlation between convalescent treatment and either death or time to negative PCR and hospitalization length. The study population included 270 patients, 100 of them treated with convalescent plasma. The results show that convalescent plasma therapy significantly prevented mortality in moderate patients, reduced hospitalization length and time to negative PCR. Additionally, high BMI, elderly age, high CRP and 4C-scores correlated with the severity and mortality of COVID-19 patients. Convalescent plasma also significantly reduced inflammatory markers, especially in moderate COVID-19 patients. In non-critical hospitalized patients, convalescent plasma therapy reduces morbidity and mortality in moderate COVID-19 patients and hospitalization length. Identifying patients who could benefit from this treatment could reduce the risk of death and shorten their hospitalization stay.Maamoun BasheerElias SaadDorin ShlezingerNimer AssyMDPI AGarticleconvalescent plasma therapymortalitymoderate COVID-19 patientstime to dischargehospitalization lengthinflammatory markersMicrobiologyQR1-502ENMetabolites, Vol 11, Iss 761, p 761 (2021)
institution DOAJ
collection DOAJ
language EN
topic convalescent plasma therapy
mortality
moderate COVID-19 patients
time to discharge
hospitalization length
inflammatory markers
Microbiology
QR1-502
spellingShingle convalescent plasma therapy
mortality
moderate COVID-19 patients
time to discharge
hospitalization length
inflammatory markers
Microbiology
QR1-502
Maamoun Basheer
Elias Saad
Dorin Shlezinger
Nimer Assy
Convalescent Plasma Reduces Mortality and Decreases Hospitalization Stay in Patients with Moderate COVID-19 Pneumonia
description Humans infected with SARS-CoV-2 may develop COVID-19, which manifests across a wide spectrum of clinical severity ranging from mild upper respiratory tract illnesses to diffuse viral pneumonia, causing acute respiratory failure. Many therapies have been tested for their efficacy in treating COVID-19. Controversy surrounds convalescent plasma transfusions as an effective treatment for COVID-19. This study discusses the efficacy of this treatment on COVID-19 patients. Electronic medical record data were collected from patients diagnosed with COVID-19, from November 2020 to August 2021, in the Galilee Medical Center’s COVID-19 departments. Epidemiological, clinical, laboratory and imaging variables were analyzed. Multivariate stepwise regression and discriminant analyses were used to identify and validate the correlation between convalescent treatment and either death or time to negative PCR and hospitalization length. The study population included 270 patients, 100 of them treated with convalescent plasma. The results show that convalescent plasma therapy significantly prevented mortality in moderate patients, reduced hospitalization length and time to negative PCR. Additionally, high BMI, elderly age, high CRP and 4C-scores correlated with the severity and mortality of COVID-19 patients. Convalescent plasma also significantly reduced inflammatory markers, especially in moderate COVID-19 patients. In non-critical hospitalized patients, convalescent plasma therapy reduces morbidity and mortality in moderate COVID-19 patients and hospitalization length. Identifying patients who could benefit from this treatment could reduce the risk of death and shorten their hospitalization stay.
format article
author Maamoun Basheer
Elias Saad
Dorin Shlezinger
Nimer Assy
author_facet Maamoun Basheer
Elias Saad
Dorin Shlezinger
Nimer Assy
author_sort Maamoun Basheer
title Convalescent Plasma Reduces Mortality and Decreases Hospitalization Stay in Patients with Moderate COVID-19 Pneumonia
title_short Convalescent Plasma Reduces Mortality and Decreases Hospitalization Stay in Patients with Moderate COVID-19 Pneumonia
title_full Convalescent Plasma Reduces Mortality and Decreases Hospitalization Stay in Patients with Moderate COVID-19 Pneumonia
title_fullStr Convalescent Plasma Reduces Mortality and Decreases Hospitalization Stay in Patients with Moderate COVID-19 Pneumonia
title_full_unstemmed Convalescent Plasma Reduces Mortality and Decreases Hospitalization Stay in Patients with Moderate COVID-19 Pneumonia
title_sort convalescent plasma reduces mortality and decreases hospitalization stay in patients with moderate covid-19 pneumonia
publisher MDPI AG
publishDate 2021
url https://doaj.org/article/39c341d34bd845b8a70eddb50ac35c47
work_keys_str_mv AT maamounbasheer convalescentplasmareducesmortalityanddecreaseshospitalizationstayinpatientswithmoderatecovid19pneumonia
AT eliassaad convalescentplasmareducesmortalityanddecreaseshospitalizationstayinpatientswithmoderatecovid19pneumonia
AT dorinshlezinger convalescentplasmareducesmortalityanddecreaseshospitalizationstayinpatientswithmoderatecovid19pneumonia
AT nimerassy convalescentplasmareducesmortalityanddecreaseshospitalizationstayinpatientswithmoderatecovid19pneumonia
_version_ 1718411312538583040